Bicycle therapeutics to present radiopharmaceuticals data at european association of nuclear medicine 2024 congress

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called bicycle radionuclide conjugates (brc®), at the european association of nuclear medicine (eanm) 2024 congress taking place.
BCYC Ratings Summary
BCYC Quant Ranking